Kilitch Drugs India Ltd

Kilitch Drugs India Ltd

Kilitch Drugs India Ltd has submitted the scrutinizer's report for the 34th Annual General Meeting, which was held on August 27, 2026, through video conferencing. The report details the voting results for the resolutions passed at the meeting, including the adoption of the audited standalone and consolidated financial statements for the year ended March 31, 2026, and the appointment of Mr. Mukund P. Mehta as a director who retires by rotation.

Kilitch Drugs India Ltd

Kilitch Drugs India Ltd has held its 34th Annual General Meeting (AGM) through video conferencing, where resolutions related to financial statements, director reappointment, performance-linked pay, and cost auditor remuneration were passed.

Kilitch Drugs India Ltd

Kilitch Drugs India Ltd submitted a monitoring agency report for the quarter ended June 30, 2026, as per SEBI Regulations and Monitoring Agency Agreement. The report indicates no deviation from the objects of the issue and provides an objective view of the utilization of the issue proceeds.

Kilitch Drugs India Ltd

Kilitch Drugs India Ltd has published the extract of its financial results for the quarter ended 30th June 2026, with total income from operations at ₹556.14 lakhs and net profit for the period at ₹12.315 lakhs.

Kilitch Drugs India Ltd

Kilitch Drugs India Ltd has announced its unaudited financial results for the quarter ended 30th June 2026, with a net profit of Rs. 505.24 lakhs and earnings per share of Rs. 1.45.

Kilitch Drugs India Ltd

Kilitch Drugs India Ltd has announced its unaudited financial results for the quarter ended 30th June 2026, with a net profit of Rs. 505.24 lakhs and earnings per share of Rs. 1.45.

Kilitch Drugs India Ltd

Kilitch Drugs India Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 to consider and approve unaudited standalone and consolidated financial results for the quarter ended 30th June, 2026.

Kilitch Drugs India Ltd

Kilitch Drugs India Ltd has announced the publication of the Notice of AGM, Book Closure, E-voting, and availability of Annual Report for the Financial Year 2025-26 in the Free Press Journal and Nava Shakti newspapers. The company has also announced the sale of property through private treaty under the provisions of the SARFAESI Act, 2002.

Kilitch Drugs India Ltd

Kilitch Drugs India Ltd has issued a letter to shareholders who have not registered their email addresses with the company or its registrar, providing a weblink to access the Annual Report for FY 2025-26 and Notice of AGM. The company has also requested shareholders to update their KYC details and dematerialize physical securities.

Kilitch Drugs India Ltd

Kilitch Drugs India Ltd has announced a book closure and annual general meeting, with the register of members and share transfer register to be closed from August 20 to August 27, 2026. The company will hold its 34th annual general meeting on August 27, 2026, through video conferencing and other audio visual means. Members will be able to exercise their votes electronically for transacting the items of business.

Kilitch Drugs India Ltd

Kilitch Drugs India Ltd submitted its annual report for FY 2025-26, along with a notice of the 34th Annual General Meeting, scheduled for August 27, 2026. The report highlights the company's financial performance, manufacturing excellence, and commitment to innovation, quality, and sustainability.

Kilitch Drugs India Ltd

Kilitch Drugs India Ltd has announced the notice of its 34th Annual General Meeting (AGM) to be held on August 27, 2026, through video conferencing or other audio visual means. The meeting will consider and pass resolutions related to the adoption of financial statements, appointment of directors, and remuneration to executive directors and cost auditor.

Kilitch Drugs India Ltd

Kilitch Drugs India Ltd announced the outcome of its board meeting, approving the notice of its 34th Annual General Meeting (AGM) to be held on August 27, 2026, through video conferencing. The board also approved the Directors Report, Corporate Governance Report, and the appointment of a scrutinizer for the AGM. Additionally, the company re-appointed its cost auditors, M/s Arvind Kumar & Co. Cost Accountants, for the financial year 2026-27.